Home/ Stocks/ STTK

Shattuck Labs, Inc. Common Stock

STTK XNAS

$7.27 +0.08 (+1.12%) ▲ 15-min delayed

Open

$7.30

High

$7.42

Low

$7.21

Volume

894.5K

Market Cap

$683.84M

About Shattuck Labs, Inc. Common Stock

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 40 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-14,767,000	$-0.13
FY 2025	$1.00M	$-48,809,000	$-0.70
Q3 2025	$1.00M	$-10,056,000	$-0.14
Q2 2025	$0	$-12,458,000	$-0.24

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for STTK yet. Check out our latest market news or earnings calendar.

Get STTK Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Shattuck Labs, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.